Multiple System Atrophy Pipeline Therapeutics Assessment 2017 Multiple System Atrophy Pipeline Drugs and Therape

Multiple System Atrophy Pipeline Drugs and Therapeutics Review H1 2017 provide an overview of
the Multiple System Atrophy (Central Nervous System) pipeline landscape. Pharmaceutical and
Healthcare latest pipeline guide Multiple System Atrophy - Pipeline Review, H1 2017, provides
comprehensive information on the therapeutics under development for Multiple System Atrophy
(Central Nervous System), complete with analysis by stage of development, drug target, mechanism
of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and development history and
latest news and press releases.
Inquire for Complete 33 Pages PDF Report at:
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1057929 .
Multiple System Atrophy (Central Nervous System) pipeline therapeutics guide also reviews of key
players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager
Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The
guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 3 and 1
respectively. Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that
impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion).
Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation,
incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-
Parkinson's medications.
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies
Involved in Therapeutics Development Discussed: AFFiRiS AG, Corestem Inc, Neuropore Therapies
Inc, Prana Biotechnology Ltd.
Multiple System Atrophy Drug Profiles Discussed: Anle-138b, CS-10BR05, ENT-01, NPT-20011, PBT-
434, PD-01, PD-03, Small Molecules for Neurodegenerative Disease.
Report available with Discount at
http://www.reportsnreports.com/contacts/discount.aspx?name=1057929
Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision making capabilities and helps
to create effective counter strategies to gain competitive advantage. The guide is built using data
and information sourced from Global Markets Direct’ s proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third party sources. Additionally,
various dynamic tracking processes ensure that the most recent developments are captured on a
real time basis.
Scope:
1. The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System
Atrophy (Central Nervous System).